Overcoming Bioavailability Challenges Through Particle-Size Engineering to be Presented at Upcoming CPhI Japan Conference by Catalent Expert

Share Article

Catalent Pharma Solutions (Booth T01), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Mr. Arnaud Bathelier, Catalent Micron Technologies, will be presenting at the upcoming CPhI Japan Conference, to be held at the Big Sight Exhibition Centre, Tokyo, Japan, on April 20th - 22nd, 2016.

Catalent Pharma Solutions (Booth T01), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Mr. Arnaud Bathelier, Catalent Micron Technologies, will be presenting at the upcoming CPhI Japan Conference, to be held at the Big Sight Exhibition Centre, Tokyo, Japan, on April 20th - 22nd, 2016.

Mr. Bathelier’s presentation, on Friday, April 22nd, at 1.45 p.m., is entitled “Micronization: A Versatile Platform for Solubility Enhancement,” and will discuss how advanced particle-size reduction techniques, including mechanical milling and micronization, can be beneficial in improving solubility and therefore the bioavailability of orally administered drugs, and in optimizing delivery through other routes of administration such as oral and nasal inhalation. The presentation will compare milling and micronization techniques, and discuss the importance of comprehensive analytical capabilities in characterizing and optimizing a formulation for rapid product development.

Mr. Bathelier joined Catalent in November 2014, following its acquisition of Micron Technologies, and now serves as Catalent Micron Technologies’ Business Development Manager, specializing in particle size engineering in Europe and Japan. Previously, Mr. Bathelier worked in business and marketing roles for Air Products and Chemicals Inc. He graduated from the Ecole Nationale Supérieure de Chimie et de Physique de Bordeaux.

Catalent will also be exhibiting at CPhI Japan where it will showcase a broad range of its drug delivery technologies and development solutions designed to increase bioavailability and drug efficacy. The company will also showcase its Asia clinical supply network solutions that can help customers overcome clinical trial challenges in the region and reduce timelines.

For more information on the CPhI exhibition and conference, visit: http://www.cphi.com/japan/ and to arrange a meeting with a Catalent executive, contact Richard Kerns at NEPR- richard(at)nepr(dot)eu.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website